Akums Drugs and Pharmaceuticals


# Akums Drugs and Pharmaceuticals



**Akums Drugs and Pharmaceuticals Limited** is an Indian pharmaceutical Contract Development and Manufacturing Organization (CDMO) that serves both domestic and multinational pharmaceutical companies. The company was established in 2004 and became publicly listed on August 6, 2024.


## History

Akums was founded by Sanjeev Jain and Sandeep Jain in 2004, who currently serve as the managing directors of the company. The company has 12 manufacturing facilities for various formulations and two facilities for producing active pharmaceutical ingredients (APIs). It produces tablets, capsules, soft gels, dry syrups, liquid orals, and other pharmaceutical products. Akums also operates four research and development (R&D) centers in India. In 2020, the company received an investment of Rs 500 crore from Quadria Capital.

In April 2022, the company acquired a manufacturing facility from Ankur Drugs and Pharmaceuticals Limited. In May, the company received a license to manufacture and commercialize Bempedoic acid, a drug used to lower cholesterol. Two of the company's units in Haridwar were granted European GMP certification. One unit produces solid oral dosage forms, such as tablets and hard gelatin capsules, while the other manufactures large and small volume parenterals, including vials, ampoules, eye drops, and FFS formulations. In August 2024, the company went public with a listing on the Bombay Stock Exchange and the National Stock Exchange.


### Partnerships

In October 2024, Akums partnered with Microcore Research to use natural eggshell membrane (NESM) in the development of dietary supplements for joint and connective tissue health.

In November 2023, Akums entered into a MoU with Delhi Pharmaceutical Sciences and Research University to collaborate on research and product development for patients in India.


## Product development

In August 2023, Akums launched a formulation for managing Type-2 Diabetes in elderly patients, which combines multiple medications to help control blood sugar levels. On September 15, 2023, it introduced a fixed-dose combination capsule of Tamsulosin and Tadalafil, containing Tamsulosin 0.4 mg and Tadalafil 2.5 mg. The company also began manufacturing nutraceutical gummies.

In December 2023, Akums acquired a formulation facility in Baddi, Himachal Pradesh, and announced the launch of Doxylamine and Pyridoxine extended-release tablets, which are approved by the Central Drugs Standard Control Organisation (CDSCO) in India and the United States Food and Drug Administration (US FDA).

In 2024, the company launched several products, including Lasmiditan tablets, nasal sprays, Hydroxyurea for sickle cell anemia, and a fixed-dose combination of Amlodipine, Telmisartan, and Metoprolol (extended-release) tablets for hypertension.

